Key facts
- This page summarizes Christopher Chapman MD's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Aug 2023, 18:00.
Christopher Chapman MD - 17 Aug 2023 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- MIRA
- Reported as of
- 17 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Aug 2023, 18:00:16 UTC
- Prior SEC filing
- 02 Aug 2023
- Next SEC filing
- 08 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Yanez, Attorney-in-Fact for Chris Chapman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Chapman MD filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 21 Aug 2023.
Change
- Previous filing in this sequence was filed on 02 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRA
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 17 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $6.50
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023.
Footnote F2
The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023.